# GROWTH HORMONE SECRETAGOGUES

## SCIENCE • SYNERGY • OPTIMAL HEALTH

### UNDERSTANDING TESAMORELIN, CJC-1295, AND IPAMORELIN

FOR PHYSIOLOGIC GH STIMULATION, RECOVERY, AND HEALTHY AGING




Mark L. Gordon, MD

EVIDENCE-BASED PEPTIDES | SYNERGISTIC COMBINATIONS | OPTIMIZED DOSING & CYCLING

# Optimization and Use of Growth Hormone Secretagogues

## Introduction

Growth Hormone Secretagogue (GHS) peptides represent a unique class of biologically active compounds designed to stimulate the body's natural production and pulsatile release of growth hormone through physiologic hypothalamic-pituitary signaling pathways. Unlike exogenous recombinant growth hormone administration, these peptides work by enhancing endogenous endocrine function, thereby preserving many of the body's natural regulatory feedback systems. Through activation of either Growth Hormone Releasing Hormone (GHRH) receptors, ghrelin receptors (GHS-R1a), or both, these peptides can promote increases in growth hormone and insulin-like growth factor-1 (IGF-1), which play critical roles in tissue repair, mitochondrial energy production, neuroregeneration, protein synthesis, body composition, immune modulation, metabolic regulation, sleep architecture, and healthy aging physiology.

What makes Growth Hormone Secretagogues particularly attractive in translational and regenerative medicine is their ability to be utilized either individually or synergistically in combination. Certain peptides such as Tesamorelin and CJC-1295 primarily stimulate the GHRH receptor pathway, while peptides such as Ipamorelin selectively activate ghrelin-mediated signaling. When combined, these distinct mechanisms may produce amplified physiologic pulsatility of growth hormone release that more closely mimics youthful endocrine function. This synergistic approach has led to increasing interest in their use for supporting recovery from physical stress, improving body composition, preserving lean muscle mass during aging, enhancing connective tissue repair, improving sleep quality, supporting neurocognitive resilience, and optimizing recovery in individuals experiencing chronic inflammatory, metabolic, or neuroendocrine dysfunction.

An additional advantage of many modern GH secretagogues is their improved safety profile compared with earlier generations of growth hormone stimulants or direct recombinant growth hormone therapy. Because endogenous feedback regulation through somatostatin and IGF-1 remains largely intact, the risk of sustained supraphysiologic growth hormone exposure may be reduced when these compounds are appropriately dosed and monitored. Furthermore, newer selective peptides such as Ipamorelin demonstrate minimal stimulation of cortisol and prolactin secretion, thereby offering more targeted anabolic and restorative benefits with fewer unwanted endocrine side effects. As research in peptide therapeutics continues to evolve, Growth Hormone Secretagogues are increasingly being explored not only for performance and anti-aging applications, but also for their broader potential roles in regenerative medicine, neuroendocrinology, metabolic health, and recovery biology.

## The GH Secretagogues

### Tesamorelin

Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) specifically engineered to stimulate the pituitary gland to increase endogenous pulsatile growth hormone (GH) secretion while preserving normal physiologic feedback regulation. What makes Tesamorelin unique among GH secretagogues is its extensive clinical validation and FDA approval for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. Unlike direct exogenous growth hormone administration, Tesamorelin promotes a more physiologic pattern of GH release, thereby reducing the risk of supraphysiologic GH exposure and many of the adverse effects associated with recombinant GH therapy. Tesamorelin has demonstrated significant benefits on abdominal visceral fat reduction, IGF-1 elevation within controlled physiologic ranges, mitochondrial energy support, and potentially improved cognitive

parameters through enhanced neurotrophic signaling and blood-brain barrier support. Mechanistically, Tesamorelin acts through GHRH receptors on somatotroph cells of the anterior pituitary, leading to increased cyclic AMP signaling and pulsatile GH release. One of its notable safety advantages is that endogenous somatostatin feedback remains intact, helping to minimize excessive GH secretion. Compared with older GHRH analogs, Tesamorelin appears to have a relatively favorable metabolic profile with less tendency toward fluid retention or insulin dysregulation when properly dosed and monitored.

**CJC-1295**

CJC-1295 is a long-acting GHRH analog designed to significantly extend the half-life of endogenous GH stimulation through its affinity for albumin binding. Its primary uniqueness lies in the Drug Affinity Complex (DAC) technology found in one formulation, which allows prolonged stimulation of pituitary GH release over several days rather than minutes or hours. This prolonged pharmacokinetic profile creates sustained elevations in GH and IGF-1 while still utilizing the body's own physiologic endocrine pathways rather than bypassing them with exogenous GH. CJC-1295 is highly valued in translational and performance medicine because it may support improved body composition, lean muscle preservation, sleep architecture, tissue recovery, mitochondrial efficiency, collagen synthesis, and neuroregenerative processes. Compared with many shorter-acting GH secretagogues, CJC-1295 generally produces less dramatic hormonal fluctuation and may provide more stable IGF-1 support. From a safety standpoint, CJC-1295 preserves normal hypothalamic-pituitary feedback mechanisms, reducing the likelihood of complete endocrine suppression. In contrast to more aggressive GH-stimulating agents, it has a relatively low incidence of cortisol or prolactin elevation because it acts primarily through the GHRH receptor pathway rather than direct ghrelin receptor overstimulation. The non-DAC version of CJC-1295 offers shorter physiologic pulsatility and is sometimes preferred clinically when tighter dosing control is desired.

**Ipamorelin**

Ipamorelin is a highly selective Growth Hormone Secretagogue Receptor (GHS-R1a) agonist that mimics the biologic actions of ghrelin while demonstrating exceptional receptor specificity. What distinguishes Ipamorelin from earlier growth hormone releasing peptides such as GHRP-2 and GHRP-6 is its ability to stimulate robust pulsatile GH release with minimal influence on cortisol, prolactin, aldosterone, or excessive appetite stimulation. This receptor selectivity provides a superior safety and tolerability profile, making Ipamorelin one of the most clinically favored GH secretagogues for long-term physiologic support. Ipamorelin acts primarily at the hypothalamic and pituitary levels by activating ghrelin receptors, which enhances endogenous GH pulsatility while maintaining intact negative feedback regulation. Clinically, Ipamorelin is associated with improvements in sleep quality, tissue repair, exercise recovery, lean body mass maintenance, connective tissue healing, and potentially neuroprotective and anti-inflammatory effects through IGF-1 mediated pathways. Because it produces less stimulation of ACTH and cortisol secretion compared with older GHRPs, Ipamorelin may be particularly advantageous in individuals already experiencing chronic stress physiology, neuroinflammation, or HPA-axis dysregulation. Another safety advantage is its lower tendency to produce significant water retention, paresthesia, or excessive hunger, which are more commonly observed with less selective secretagogues.

## The analysis of GH Secretagogues; single use and in combination

### Best Single Peptide: Tesamorelin

For individuals seeking a regulated, evidence-based Growth Hormone Secretagogue with broad physiologic and metabolic benefits, Tesamorelin remains one of the strongest single-peptide options currently available. Tesamorelin is an FDA-approved Growth Hormone Releasing Hormone (GHRH) analog that stimulates the body's natural production of growth hormone and downstream insulin-like growth factor-1 (IGF-1) through activation of the pituitary GHRH receptor. Although its formal FDA indication is for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy, its biologic actions extend well beyond this specific population and have generated significant interest in translational, metabolic, and regenerative medicine.

From a general health perspective, Tesamorelin may support reductions in visceral abdominal fat, improvements in body composition, enhanced lean muscle preservation, improved recovery physiology, mitochondrial energy support, and optimization of sleep architecture through restoration of more youthful pulsatile growth hormone signaling. In addition, increasing evidence suggests that physiologic enhancement of GH and IGF-1 pathways may positively influence cognitive resilience, neuroplasticity, connective tissue repair, cardiovascular metabolism, and healthy aging biology when properly monitored.

One of Tesamorelin's major advantages is that it stimulates endogenous hormone production rather than replacing growth hormone directly. This allows normal hypothalamic-pituitary feedback regulation to remain largely intact, potentially reducing the risks associated with sustained supraphysiologic growth hormone exposure seen with direct recombinant GH administration. Compared with many other GH secretagogues, Tesamorelin also possesses one of the strongest human clinical data profiles, making it an attractive option for individuals seeking a more medically validated and physiologically regulated approach to supporting metabolic health, recovery, and age-related endocrine optimization.

### Best Synergistic Pair: CJC-1295 + Ipamorelin

The combination of CJC-1295 and Ipamorelin is widely regarded as one of the most biologically complementary and physiologically balanced Growth Hormone Secretagogue pairings available. This synergy is created through activation of two separate, but cooperative pathways involved in endogenous growth hormone regulation. CJC-1295 functions as a long-acting Growth Hormone Releasing Hormone (GHRH) analog that stimulates pituitary somatotroph cells through the GHRH receptor, thereby enhancing the body's natural pulsatile growth hormone production. Ipamorelin, in contrast, acts selectively through the ghrelin or Growth Hormone Secretagogue Receptor-1a (GHSR-1a), creating a second and independent signal for growth hormone release.

When utilized together, these two pathways work synergistically to amplify physiologic growth hormone pulsatility in a manner that more closely resembles youthful endocrine function. This dual-receptor stimulation may support more consistent elevations in growth hormone and IGF-1 while preserving normal hypothalamic-pituitary feedback regulation. From a translational and regenerative medicine perspective, the combination has become increasingly popular for supporting reductions in visceral adiposity, preservation of lean muscle mass, connective tissue repair, exercise recovery, sleep quality, mitochondrial energy production, and healthy aging physiology.

An important advantage of this pairing is its relatively favorable safety and tolerability profile compared with older generations of growth hormone secretagogues. Ipamorelin demonstrates high receptor selectivity with minimal stimulation of cortisol, prolactin, or excessive appetite, while CJC-1295 provides prolonged and stable GHRH-mediated signaling. Together, the combination may produce a smoother and more physiologic anabolic and restorative effect without many of the undesirable endocrine fluctuations associated with more aggressive growth hormone stimulation strategies. Because both peptides enhance endogenous hormone signaling rather than replacing growth hormone directly, they are often viewed as a

more physiologically regulated approach to optimizing recovery biology, metabolic health, and neuroendocrine resilience.

**Why Ipamorelin Is Attractive**

Ipamorelin has become one of the most clinically attractive Growth Hormone Secretagogues because of its highly selective mechanism of action and comparatively favorable safety profile. Among the older GHRP-style secretagogues, Ipamorelin is often regarded as the "cleanest" option due to its ability to stimulate pulsatile growth hormone release with minimal activation of other hormonal pathways. Specifically, Ipamorelin acts selectively at the Growth Hormone Secretagogue Receptor-1a (GHSR-1a), allowing it to enhance endogenous growth hormone secretion while producing significantly less stimulation of adrenocorticotropic hormone (ACTH), cortisol, prolactin, and aldosterone compared with earlier agents such as GHRP-6, GHRP-2, or Hexarelin.

This receptor specificity provides several practical and physiologic advantages. Reduced cortisol stimulation may be particularly beneficial in individuals already experiencing chronic stress physiology, neuroinflammation, sleep disruption, overtraining, metabolic dysfunction, or hypothalamic-pituitary-adrenal (HPA) axis dysregulation. In addition, Ipamorelin generally produces less excessive hunger, fluid retention, or endocrine instability than many of the earlier generation secretagogues, making it better tolerated during longer-term use.

From a translational medicine perspective, Ipamorelin's selective GH-releasing properties may support improved sleep architecture, tissue repair, lean muscle preservation, connective tissue healing, exercise recovery, mitochondrial energy production, and healthy aging physiology while maintaining more physiologic endocrine balance. Because it stimulates endogenous growth hormone pulsatility rather than replacing growth hormone directly, normal feedback regulation remains largely intact, which further contributes to its appeal as a more controlled and physiologically harmonious peptide therapy option.

## The Single Applications of GHS

Growth Hormone Secretagogues are typically used with the goal of enhancing physiologic pulsatility of GH and IGF-1 rather than creating sustained supraphysiologic exposure. Because these peptides work through endogenous signaling pathways, dosing strategies are generally designed to optimize receptor responsiveness while minimizing homologous desensitization, excessive IGF-1 elevation, edema, insulin resistance, or receptor downregulation. Clinical and translational medicine approaches therefore often favor conservative physiologic dosing combined with cycling intervals that allow restoration of receptor sensitivity and hypothalamic-pituitary feedback integrity.

**Tesamorelin**

Tesamorelin is typically utilized as a once-daily evening injection because its biologic action most closely mimics physiologic nocturnal growth hormone release. The FDA-approved dose for visceral adiposity reduction is 2 mg subcutaneously daily; however, in translational or regenerative medicine settings, many clinicians utilize lower physiologic doses ranging from 0.5 mg to 1 mg nightly initially, with titration based upon IGF-1 response, metabolic tolerance, sleep quality, and body composition goals. Because Tesamorelin has a relatively potent and sustained influence on IGF-1 production, careful monitoring of fasting glucose, HbA1c, IGF-1, and fluid retention is recommended.

From a cycling standpoint, Tesamorelin is commonly used continuously for 8–16 weeks, followed by a 2–6-week reduction phase or temporary discontinuation depending upon clinical response and IGF-1 levels. Some practitioners prefer "5 days on / 2 days off" schedules to reduce receptor accommodation and maintain physiologic responsiveness. Due to its strong GHRH-mediated signaling and long-term IGF-1 elevation potential, periodic breaks are often considered beneficial to preserve pituitary sensitivity and minimize chronic overstimulation.

### CJC-1295

The dosing strategy for CJC-1295 depends significantly upon whether the DAC (Drug Affinity Complex) or non-DAC formulation is being utilized. The DAC version has a substantially prolonged half-life and is often dosed at 1–2 mg once or twice weekly. In contrast, the non-DAC version behaves more like physiologic pulsatile GHRH and is commonly dosed at 100–300 mcg one to three times daily, often timed around fasting states, exercise, or pre-sleep periods to amplify endogenous GH pulses.

Clinically, the non-DAC formulation is frequently favored for individuals seeking tighter physiologic control and reduced risk of continuous receptor stimulation, whereas DAC formulations may offer convenience and more stable IGF-1 support. Cycling commonly involves 8–12 week treatment phases followed by a 2–4 week break to reduce the possibility of GHRH receptor desensitization. Some clinicians utilize lower-dose maintenance schedules after initial cycling phases rather than complete discontinuation. Combining CJC-1295 with a ghrelin receptor agonist such as Ipamorelin often allows lower individual dosing while maintaining enhanced biologic synergy.

### Ipamorelin

Ipamorelin is generally utilized at doses ranging from 100–300 mcg per injection, administered one to three times daily depending upon clinical objectives and whether it is being used alone or in combination with a GHRH analog such as CJC-1295. The most common translational medicine approach involves administration before bedtime to augment nocturnal GH release, although additional morning or post-exercise dosing may be employed in performance or recovery-oriented protocols. Because insulin and elevated glucose may blunt endogenous GH pulsatility, Ipamorelin is frequently administered in relatively fasted states.

One of Ipamorelin's major advantages is its relatively low tendency toward cortisol or prolactin elevation, allowing for longer-term tolerability compared with older GHRPs. Nevertheless, receptor accommodation may still occur over time. Common cycling strategies include 5 days on / 2 days off, or 8–12 week treatment periods followed by a 2–4 week break. In combination protocols with CJC-1295, lower Ipamorelin doses of approximately 100–200 mcg nightly are often sufficient due to the biologic synergy between GHRH and ghrelin receptor stimulation pathways.

### General Clinical Perspective

For most individuals seeking physiologic restoration, recovery support, or healthy aging benefits, conservative dosing strategies with periodic cycling appear to provide the most balanced approach. Excessive dosing may increase the risk of edema, carpal tunnel symptoms, insulin resistance, headaches, sleep disruption, or receptor desensitization without necessarily improving long-term outcomes. In translational medicine, the objective is generally not maximal GH elevation, but rather restoration of healthier pulsatile endocrine signaling patterns that support recovery biology, neuroendocrine resilience, mitochondrial efficiency, tissue repair, and metabolic optimization.

## Combination Growth Hormone Secretagogue Protocols

When Growth Hormone Secretagogues (GHS) are utilized in combination, the clinical objective is generally to create synergistic physiologic stimulation of endogenous growth hormone release while minimizing receptor desensitization, endocrine overstimulation, excessive IGF-1 elevation, and metabolic adverse effects. The most biologically rational combinations typically pair a GHRH analog, which stimulates pituitary somatotroph cells through the GHRH receptor pathway, with a ghrelin receptor agonist, which activates the Growth Hormone Secretagogue Receptor-1a (GHSR-1a). This dual-pathway activation amplifies physiologic GH pulsatility in a manner more closely resembling youthful neuroendocrine function.

Because endogenous GH secretion is naturally pulsatile and strongly influenced by circadian rhythm, sleep state, insulin levels, and fasting physiology, dosing schedules are commonly timed around fasting periods, exercise recovery, and nighttime sleep initiation. Conservative dosing with periodic cycling is generally favored in translational and regenerative medicine to preserve receptor responsiveness and maintain physiologic endocrine balance.

## CJC-1295 (Non-DAC) + Ipamorelin

This combination is widely considered one of the most physiologically balanced and synergistic GH secretagogue pairings available. CJC-1295 without DAC provides pulsatile GHRH receptor stimulation, while Ipamorelin selectively activates ghrelin receptors with minimal cortisol or prolactin stimulation.

A common physiologic protocol involves:

- CJC-1295 (Non-DAC): 100–200 mcg
- Ipamorelin: 100–300 mcg

These are frequently administered together one to three times daily depending upon therapeutic goals. The most common and practical regimen is:

- Morning fasting dose
- Optional post-exercise or afternoon fasting dose
- Pre-bedtime dose

For general wellness, recovery, sleep optimization, and healthy aging support, many clinicians favor a simplified once-nightly or twice-daily protocol:

- 100–150 mcg CJC-1295 (Non-DAC)
- 100–200 mcg Ipamorelin

The combination is ideally administered in a relatively fasted state, typically avoiding caloric intake for approximately 60–90 minutes before and 20–30 minutes after administration to optimize endogenous GH pulsatility.

Cycling commonly involves:

- 5 days on / 2 days off or
- 8–12 weeks on followed by 2–4 weeks off

Longer-term lower-dose maintenance strategies may also be utilized after initial cycling phases to preserve receptor sensitivity while maintaining physiologic benefits.

## CJC-1295 (DAC) + Ipamorelin

The DAC formulation of CJC-1295 provides prolonged albumin-bound GHRH activity lasting several days, creating more stable IGF-1 support and reducing injection frequency. Because DAC already produces sustained stimulation, lower-frequency administration of Ipamorelin is often sufficient.

Typical dosing includes:

- CJC-1295 DAC: 1–2 mg once weekly or
- 500–1000 mcg twice weekly

Combined with:

- Ipamorelin: 100–300 mcg nightly or
- 100–200 mcg twice daily

The bedtime administration of Ipamorelin is often emphasized because it aligns with natural nocturnal GH secretion patterns and may improve sleep architecture and tissue recovery.

Cycling commonly involves:

- 8–12 weeks on followed by
- 2–6 weeks off

Because DAC formulations create more prolonged receptor stimulation and sustained IGF-1 elevation, periodic off-cycles are generally considered more important to reduce homologous desensitization and endocrine accommodation.

## *Tesamorelin + Ipamorelin (IN STOCK)

Although less commonly utilized than CJC-1295 combinations, Tesamorelin paired with Ipamorelin represents a potentially effective strategy for individuals seeking stronger metabolic and visceral adiposity support while preserving physiologic GH pulsatility.

**Most practical anti-aging / recovery protocol**

- Dose: **0.5 mg Tesamorelin + 0.5 mg Ipamorelin nightly**
- Duration: ~20 days

This is the dose I most commonly see used when practitioners are attempting to balance efficacy and peptide cost. Each of our dispensed bottles of Tesamorelin/Ipamorelin has 10mg of each peptide. We recommend adding either 2cc of BSW and using 10(.1cc) at bedtime or adding 4cc of BSW and using 20(.2cc) at bedtime. Either way delivers 500mcg of each peptide. The only difference is the volume of solution.

A conservative translational medicine protocol often includes:

- Tesamorelin: 0.5–1 mg nightly combined with
- Ipamorelin: 100–200 mcg nightly

In some higher-response protocols:

- Tesamorelin may be increased toward 2 mg nightly
  depending upon IGF-1 response, metabolic tolerance, glucose regulation, and fluid retention.

Because both compounds significantly influence GH and IGF-1 physiology, clinicians generally favor lower starting doses with careful monitoring of:

- IGF-1
- fasting glucose
- HbA1c
- edema
- sleep quality
- body composition

Cycling frequently involves:

- 8–16 weeks on followed by
- 4 weeks off or dose reduction

Some practitioners employ a:

- 5 days on / 2 days off
  approach to reduce continuous receptor exposure.

### Tesamorelin + CJC-1295

This combination is less commonly recommended because both peptides primarily stimulate the GHRH receptor pathway. While additive GH stimulation may occur, the biologic synergy is generally less substantial than combining a GHRH analog with a ghrelin receptor agonist. In addition, excessive or continuous GHRH receptor stimulation may theoretically increase the risk of receptor accommodation and excessive IGF-1 elevation.

If utilized, conservative dosing is generally recommended:

- Tesamorelin: 0.5–1 mg nightly
- CJC-1295 DAC: 500–1000 mcg weekly or
- Non-DAC: 100 mcg nightly

Aggressive dosing of both simultaneously is generally avoided in physiologic restoration protocols.

## General Physiologic Principles for Combination Therapy

The ideal use of combination GH secretagogues is not maximal GH elevation, but restoration of healthier endocrine pulsatility and improved recovery biology. Lower physiologic dosing often produces superior long-term tolerability compared with aggressive supraphysiologic stimulation strategies. Excessive GH or IGF-1 elevation may increase the risk of edema, paresthesia, insulin resistance, sleep disruption, headaches, or receptor desensitization without proportionate clinical benefit.

For most individuals focused on healthy aging, metabolic support, recovery physiology, sleep quality, neuroendocrine resilience, and body composition optimization, the combination of:

- CJC-1295 (Non-DAC) + Ipamorelin
  at conservative nightly or twice-daily dosing remains one of the most balanced and clinically favored approaches.

## Practical Literature Ranking

| Category | Rating | Reason |
|---|---|---|
| Mechanistic synergy | **High** | Tesamorelin activates the GHRH receptor; Ipamorelin activates the GHSR/ghrelin receptor. These are complementary GH-release pathways. |
| Direct clinical evidence for the combination | **Low** | Evidence supports each peptide separately, but not the paired protocol. |
| Evidence for Tesamorelin alone | **High** | FDA-approved; human trials show reduction in visceral adiposity in HIV lipodystrophy. |
| Evidence for Ipamorelin alone | **Moderate/limited** | Strong endocrine-selectivity data, mostly preclinical/early-stage; less human clinical outcome evidence. |
| Safety confidence for the combination | **Moderate-low** | Both raise GH/IGF-1 signaling; additive IGF-1 elevation, edema, arthralgia, insulin resistance, or glucose effects must be monitored. |

## Practical ranking

| Goal | Best choice |
|---|---|
| Most evidence-based / regulated | **Tesamorelin** |
| Best GH-axis synergy | **CJC-1295 + Ipamorelin** |
| Cleanest secretagogue add-on | **Ipamorelin** |
| Visceral abdominal fat focus | **Tesamorelin** |
| Broader recovery / sleep / body composition concept | **CJC-1295 + Ipamorelin** |

## References


1. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S. J., Richmond, G., Fessel, W. J., Turner, R., & Grinspoon, S. K. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. *The New England Journal of Medicine*, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
2. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. *JAMA*, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
3. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. *The Journal of Clinical Endocrinology & Metabolism*, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
4. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. *European Journal of Endocrinology*, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
5. Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1984/1990). Growth hormone-releasing peptide stimulates growth hormone release in normal men and acts synergistically with growth hormone-releasing hormone. *The Journal of Clinical Endocrinology & Metabolism*, 70(4), 975–982. PMID: 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/
6. Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. *European Journal of Endocrinology*, 136(5), 445–460. PMID: 9186261. https://pubmed.ncbi.nlm.nih.gov/9186261/
7. U.S. Food and Drug Administration. (2025). *EGRIFTA WR® prescribing information: Tesamorelin for injection*. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
8. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. *The Journal of Clinical Endocrinology & Metabolism*, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
9. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. *European Journal of Endocrinology*, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552

10. Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1990). On the in vitro and in vivo activity of growth hormone-releasing peptide. *The Journal of Clinical Endocrinology & Metabolism*, 70(4), 975–982. PMID: 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/
11. Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. *European Journal of Endocrinology*, 136(5), 445–460. PMID: 9186261. https://pubmed.ncbi.nlm.nih.gov/9186261/
12. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S. J., Richmond, G., Fessel, W. J., Turner, R., & Grinspoon, S. K. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. *The New England Journal of Medicine*, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
13. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne J-P, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. *J Clin Endocrinol Metab.* 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
14. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. *J Clin Endocrinol Metab.* 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702.
15. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. *N Engl J Med.* 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375.
16. Falutz J, Mamputu J-C, Potvin D, et al. Effects of tesamorelin (TH9507)… pooled analysis of two phase 3 trials with safety extension. *J Clin Endocrinol Metab.* 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490.
17. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral and liver fat in HIV-infected patients with abdominal fat accumulation: randomized clinical trial. *JAMA.* 2014;312(4):380-389. doi:10.1001/jama.2014.8334.
18. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin in humans: comparison and interactions with hexarelin and GHRH. *J Clin Endocrinol Metab.* 2001;86(3):1169-1174. doi:10.1210/jcem.86.3.7314.
19. Camiña JP, Lodeiro M, Ischenko O, et al. Desensitization and endocytosis mechanisms of the ghrelin receptor (GHS-R1a). *Endocrinology.* 2004;145(2):930-940. doi:10.1210/en.2003-0903.
20. Hansen BS, Gerlach LO, Hansen A, Foged C, Andersen PH. The growth hormone–releasing hormone receptor: desensitisation following short-term agonist exposure. *Pharmacol Toxicol.* 2001;88(2):81-88. doi:10.1034/j.1600-0773.2001.d01-87.x.
21. Maison P, Chanson P. Impact of GH treatment on body composition and cardiovascular risk factors in adults with GH deficiency: a meta-analysis. *J Clin Endocrinol Metab.* 2004;89(5):2192-? [meta-analysis].
22. Hoffman AR, Kuntze JE, Baptista J, et al. GH replacement in adult-onset GH deficiency: effects on body composition in a randomized, placebo-controlled trial. *J Clin Endocrinol Metab.* 2004;89(5):2048-2056. doi:10.1210/jc.2003-030346.
23. Díez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone for adults with GHD: an update. *Endocrinol Metab Clin North Am.* 2018;47(2):?-? (review of body-composition and metabolic effects).
24. Wrigley S, Arafa D, Tropea D. Insulin-like growth factor-1: at the crossroads of brain development and aging. *Front Cell Neurosci.* 2017;11:14.

25. Labandeira-García JL, Costa-Besada MA, Labandeira CM, Villar-Cheda B, Rodríguez-Pallares J. IGF-1 and neuroinflammation. *Front Aging Neurosci.* 2017;9:365.
26. Hage C, Salvatori R. Growth hormone and aging. *Endocrinol Metab Clin North Am.* 2023;52(2):245-257. doi:10.1016/j.ecl.2022.10.003.
27. Milman S, Huffman DM, Barzilai N. The somatotropic axis in human aging. *Cell Metab.* 2016;23(6):980-989.